Axalimogene filolisbac

{
  "id": "MLC-T-ONC-011828",
  "term": "Axalimogene filolisbac",
  "field": "Oncology and biomedicine",
  "definition": "A cancer vaccine containing a live-attenuated strain of the bacterium Listeria monocytogenes (Lm) encoding human papillomavirus (HPV) type 16 E7 fused to a non-hemolytic listeriolysin O protein with potential immunostimulatory and antineoplastic activities. Upon vaccination with axalimogene filolisbac, Listeria expresses the HPV 16 E7 antigen and activates the immune system to mount a cytotoxic T-lymphocyte (CTL) response against cancer cells expressing HPV 16 E7. This may result in tumor cell lysis. In addition, the Listeria vector itself may induce a potent immune response. HPV 16 E7, a cell surface glycoprotein and tumor associated antigen, is overexpressed in the majority of cervical cancer cells.",
  "synonyms": [
    "attenuated live Listeria encoding HPV 16 E7 vaccine ADXS11-001",
    "ADXS11-001 vaccine",
    "attenuated live Listeria encoding HPV 16 E7 vaccine",
    "attenuated live Listeria encoding human papilloma virus 16 E7 vaccine",
    "Lovaxin-C"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/axalimogene-filolisbac/"
}